Prof Robin Foa speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the combination of dasatinib and blinatumomab for the front-line treatment of adult Ph-positive acute lymphoblastic leukaemia (ALL).
He explains that the addition of blinatumomab to dasatinib showed promising results with a rate of complete molecular response of around 65% compared with 25% for dasatinib alone.
Prof Foa highlights that this shows you can get a very high rate of complete molecular response without chemotherapy.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.